Amgen Inc. has agreed to pay $762 million to resolve federal litigation accusing the drug maker of marketing the anemia treatment Aranesp for unapproved uses.
The company pleaded guilty Tuesday to illegally introducing a misbranded drug into interstate commerce and will pay a $136 million fine and a $14 million forfeiture, according to the US Attorney’s Office for the Eastern District of New York.
It also agreed to a $612 million civil settlement according to a law firm connected to the case.
But the US attorney’s office declined to comment on that because the civil settlement won’t be unsealed until a Wednesday court hearing.
Amgen said in an e-mail that if the court accepts the plea and sentence, it will immediately resolve civil and criminal matters.